A parent peptide or derived peptide with CD47 / SIRPα blocking effect and its application
The CD47/SIRPα blocking polypeptide and its derived peptide prepared by the polypeptide solid phase synthesis method solves the problems of poor permeability and hematotoxicity of CD47/SIRPα blocking agents in the prior art, and achieves an effective tumor suppression and safety balance. Enhanced the phagocytic ability of macrophages.
Patent Information
- Application Number
- CN202210625323.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-06-02
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-06-02
AI Technical Summary
Existing CD47/SIRPα blockers, such as antibodies and protein drugs, have poor tissue permeability and potential hematotoxicity problems, making it difficult to achieve a good balance between safety and effectiveness, especially in tumor treatment.
A polypeptide WSMTWWNYW and its derived peptide were prepared by polypeptide solid phase synthesis method. Through amino acid mutation and fatty acid modification, a polypeptide with CD47/SIRPα blocking effect was developed, which avoided the hematotoxicity of the antibody and improved biosafety.
This polypeptide and derivative peptide can effectively block the binding of CD47 to SIRPα, enhance the phagocytosis of macrophages on tumor cells, inhibit tumor growth, and avoid hemotoxicity, which has good biosafety and application value.
Smart Images

Figure BDA0003676997310000021 
Figure BDA0003676997310000041 
Figure FDA0004754895470000011
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to a parent peptide or a derived peptide having a CD47 / SIRPα blocking effect and applications thereof. Background Art
[0002] The innate immune response is the body's first line of defense against infection and malignant tumors. Macrophages, as one of the key components of the innate immune system, regulate phagocytosis by recognizing "eat me" signals and "don't eat me" signals exposed on the surface of target cells. Among them, the transmembrane protein CD47 acts as a "don't eat me" signal. CD47 transmits the "don't eat me" signal to circulating macrophages by binding to the receptor signal regulatory protein α (SIRPα), thereby avoiding being cleared by phagocytes. However, tumor cells use surface overexpression of CD47 to block phagocytosis and escape immune surveillance for immune escape. Now more and more studies have shown that CD47 expression is closely related to the clinical characteristics and prognosis of tumor patients. For example, in patients with high-risk lung neuroendocrine tumors with Ki-67>40%, high expression of CD47 indicates poor progression-free survival. Moreover, CD47 expression is also positively correlated with adverse clinical pathological characteristics and poor prognosis of colorectal adenocarcinoma. Therefore, the key negative immune signal transmitted by CD47 molecules in the process of tumor immunity has become a research hotspot.
[0003] The SIRPα cytoplasmic domain contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which, when phosphorylated, recruit protein tyrosine phosphatases (SHP)-1 and SHP-2 containing the Src homology 2 domain (SH2). The binding of CD47 to SIRPα triggers the recruitment of downstream phosphatases, transmitting negative regulatory signals, thereby preventing macrophage phagocytosis. Currently, studies have shown that the use of CD47 blocking antibodies to interfere with the CD47 / SIRPα interaction can significantly enhance the ability of macrophages to phagocytose tumor cells in vitro, and exhibit good anti-tumor efficacy in the treatment of solid tumors or hematological malignancies. These research results have greatly promoted the development of a variety of CD47 / SIRPα blockers, including fully humanized CD47 antibodies, soluble SIRPα dimer fusion proteins, high-affinity SIRPα monomers with the Fc segment removed, and alpaca-derived CD47 nanobodies. However, antibodies and protein drugs with high molecular weight have poor tissue permeability and limited blocking effect in solid tumors. In addition, normal healthy blood cells also express high levels of CD47, making them potential targets for therapeutic antibodies. Some animal and clinical experiments have also reported that anemia and thrombocytopenia are related to the dose-limiting toxicity of CD47 antibodies. How to reduce potential side effects and maintain a good balance between safety and effectiveness of CD47 / SIRPα blockers has become an urgent task facing clinical tumor treatment.
[0004] In recent years, with the development and maturity of peptide synthesis technology and the good stability of peptide drugs, the development and clinical application of peptide drugs have been accelerated, making peptide drugs increasingly important in the field of anti-tumor treatment and becoming one of the important directions of new drug research and development. In addition, more than 80 peptide drugs have been approved for marketing worldwide, and 200-300 are in clinical trials, with broad development prospects. Blocking peptides have the characteristics of strong specificity and convenient synthesis in inhibiting protein interactions. Due to their advantages in price, immunogenicity and safety, they are often used as the first choice of candidate compounds and are widely used in the prevention, diagnosis and treatment of tumors, hepatitis, diabetes, AIDS, etc. For the CD47 target widely expressed in the peripheral circulation, blocking peptides can avoid triggering antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) compared to peptides lacking the IgG1-Fc fragment of antibodies, and can effectively reduce the off-target clearance of red blood cells while maintaining excellent blocking effects. Therefore, if a peptide that can block the binding of CD47 and receptor signal regulatory protein α (SIRPα) can be developed, it is expected to eliminate the tumor immunosuppressive effect while avoiding the problems of poor permeability and the hematotoxicity that CD47 antibodies are prone to. Summary of the invention
[0005] The invention prepares a polypeptide WSMTWWNYW by using a polypeptide solid phase synthesis method with amino acids protected by Fmoc (Fmoc-methyloxycarbonyl) or Boc (tert-butyloxycarbonyl), and mutates any amino acid at positions 3, 6, and 8 in the sequence of the polypeptide WSMTWWNYW to Q, M, Y, W, or R, or modifies the N-terminus of the polypeptide with fatty acids to obtain a derivative peptide, which can solve the problems of poor permeability and blood toxicity easily produced by CD47 antibodies while inhibiting tumor growth.
[0006] In order to achieve the above object, the technical solution of the present invention is as follows:
[0007] A parent peptide or a derived peptide, wherein the parent peptide sequence is a polypeptide as shown in SEQ ID NO.1, and the derived peptide is obtained by mutating any amino acid at positions 3, 6, and 8 in the parent peptide sequence to Q, M, Y, W, or R, or by modifying the N-terminus of the parent peptide with fatty acid.
[0008] Preferably, the configuration of the amino acids of the parent peptide is independently selected from D-form or L-form.
[0009] Preferably, the derived peptide sequence includes the polypeptides shown in SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10.
[0010] Further preferably, the fatty acid modification of the parent peptide is to use PEG4 to connect the fatty acid Fmoc-Lys(Pal-Glu-OtBu)-OH to the N-terminus of the parent peptide. After the parent peptide is modified with fatty acid, the derivative peptide with a molecular weight of 2101.302 has the following structural formula:
[0011]
[0012] Preferably, the parent peptide or derived peptide is in free form or a pharmaceutically acceptable salt.
[0013] Preferably, the parent peptide or the derived peptide is used in the preparation of anti-tumor drugs.
[0014] Preferably, the pharmaceutical composition includes injection, oral solution, powder, tablet, pill, aerosol, ointment, capsule.
[0015] Further preferably, the anti-tumor drug can be added with one or more pharmaceutically acceptable excipients, which include conventional diluents, fillers, adhesives, wetting agents, absorption enhancers, surfactants, lubricants or stabilizers in the pharmaceutical field.
[0016] Preferably, the tumor is a series of tumors associated with high expression of CD47.
[0017] The beneficial effects of the present invention are as follows:
[0018] The present invention prepares a parent peptide WSMTWWNYW (SEQ ID NO.1) by solid phase synthesis of amino acids (W, S, M, T, N, Y, Q, R) protected with Fmoc (Fmoc-methoxycarbonyl) or Boc (tert-butyloxycarbonyl), and mutates any amino acid at positions 3, 6, and 8 of the parent peptide sequence to Q, M, Y, W, and R, or connects fatty acids at the N-terminus of WSMTWWNYW using PEG4 to obtain its derivative peptide. The preparation method of the present invention is simple and easy, low in cost, and highly practical. The prepared parent peptide and derivative peptide can effectively block the binding of CD47 and SIRPа protein, thereby eliminating the immunosuppressive effect of tumors, promoting further phagocytosis of tumor cells by macrophages, and achieving the effect of inhibiting tumor growth. Moreover, the prepared polypeptide has a small molecular weight, strong specificity, and completely avoids the blood toxicity easily produced by CD47 antibodies, has good biosafety and high application value, and is conducive to the development of early diagnosis and immunotherapy of tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the technical solution of the present invention, the drawings required for use in the implementation mode will be briefly introduced below. Obviously, the drawings described below are only some implementation modes of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0020] Figure 1 is the mass spectrum of the derivative peptide obtained after the parent peptide (SEQ ID NO.1) of the present invention is modified by fatty acids;
[0021] Figure 2 is a graph showing the experimental results of blocking the interaction between human and mouse CD47 / SIRPα proteins when the concentration of the parent peptide and the derived peptide is 25 μM in Example 2;
[0022] Figure 3 This is a graph showing the experimental results of blocking the interaction between human and mouse CD47 / SIRPα proteins when the concentration of the derived peptide in Example 2 is 100 μM;
[0023] Figure 4 This is a graph showing the effects of the parent peptide (SEQ ID NO.1) and the derived peptides in Example 3 on the phagocytic effect of primary macrophages in vitro, wherein: the derived peptides are derived peptides obtained after the parent peptide (SEQ ID NO.1) is modified with fatty acids;
[0024] Figure 5 This is a graph showing the effect of the derivative peptides in Example 4 on the tumor volume of C57BL / 6 mice in the MC38 transplanted tumor model, in which: the derivative peptides are derivative peptides obtained after the parent peptide (SEQ ID NO.1) is modified with fatty acids;
[0025] Figure 6 This is a bar graph of blood routine parameters of the MC38 transplanted tumor model C57BL / 6 mice in the administration group and the control group in Example 4. In the figure: the derived peptide is a derivative peptide obtained by modifying the parent peptide (SEQ ID NO.1) with fatty acids. DETAILED DESCRIPTION
[0026] The technical solutions in the embodiments of the present invention are described clearly and completely below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other. The experimental methods in the following examples are conventional unless otherwise specified.
[0027] Example 1: Synthesis and purification of parent peptides or derived peptides with CD47 / SIRPα blocking effect
[0028] Parent peptide: WSMTWWNYW (SEQ ID NO. 1);
[0029] Derivative peptides: WSQTWSNYW (SEQ ID NO.2), WSMTWSNYW (SEQ ID NO.3), WSYT WSNYW (SEQ ID NO.4), WSWTWSNYW (SEQ ID NO.5), WSRTWSNYW (SEQ ID NO.6), WSATWWNYW (SEQ ID NO.7), WSATWSNWW (SEQ ID NO.8), WSATWSNRW (SEQ ID NO.9), WSATWSNMW (SEQ ID NO.10), fatty acid-modified derivative peptides, the mass spectrometry information of the fatty acid-modified derivative peptides is as follows Figure 1 The structural formula is shown below:
[0030]
[0031] The synthesis and purification method of the above-mentioned parent peptide or derivative peptide comprises the following steps:
[0032] (1) Rink resin was used as a carrier, and the synthesis direction was from the C-terminus to the N-terminus of the sequence. Then, amino acids (W, S, M, T, N, Y, Q, R) protected with Fmoc (methoxycarbonyl) or Boc (tert-butyloxycarbonyl), PEG4 (CAS: 557756-85-1) and fatty acid Fmoc-Lys(Pal-Glu-OtBu)-OH (CAS: 1491158-62-3) were used as raw materials (the amount added was 3 times the equivalent of the resin), and Rink resin was added respectively. 3 times the equivalent of condensing agent 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) and condensing agent N,N-diisopropylethylamine (DIEA) were coupled for 45 minutes, and then washed with N,N-dimethylformamide (DMF) and dichloromethane (DCM) alternately. When the ninhydrin Rink resin did not turn blue, the Fmoc protecting group was removed with DMF and piperidine in a ratio of 1:1, and the steps of "washing-coupling-ninhydrin-deprotection" were repeated until the last amino acid coupling was completed.
[0033] (2) using a peptide cleavage reagent [prepared with trifluoroacetic acid (TFA), thioanisole, phenol, ethanedithiol and double distilled water in a ratio of 7:9:6:6:3] to cleave the polypeptide of step (1) from the carrier Rink resin for 4 hours, adding ether precooled at 4°C to precipitate the polypeptide, then centrifuging to collect the precipitate and washing it with ether three times, and finally drying it in a fume hood to obtain a crude polypeptide;
[0034] (3) The crude polypeptide obtained in step (2) is purified by preparative reverse phase liquid chromatography (RP-HPLC) and analyzed and identified by HPLC and MS. Mobile phase A is 0.1% trifluoroacetic acid (TFA) / water, mobile phase B is acetonitrile; the linear elution gradient is 20% A-95% A; the flow rate is 10 mL / min, and the detection wavelength is 220 nm; finally, the purified polypeptide is obtained after freeze drying.
[0035] (4) The amino acids at positions 3, 6, and 8 of the purified polypeptide [parent peptide WSMTWWNYW (SEQ ID NO. 1)] obtained in step (3) were mutated to Q, M, Y, W, or R, or the fatty acid Fmoc-Lys(Pal-Glu-OtBu)-OH (CAS: 1491158-62-3) was connected to the N-terminus of the WSMTWWNYW sequence using PEG4 (CAS: 557756-85-1) to extend the polypeptide chain to obtain a derivative peptide, which was then analyzed using a triple quadrupole liquid chromatography-mass spectrometer (LCMS-8060, Shimadzu).
[0036] Example 2: Parent peptide and derived peptides block the interaction between human and mouse CD47 / SIRPα proteins
[0037] 1. Use lentiviral expression system to construct overexpression stable transfection cell line CHO-K1-hSIRPα or CHO-K1-mSIRPα, which specifically includes the following steps:
[0038] (1) According to the Human SIRPα (hSIRPα) gene sequence (Gene Bank sequence number: BC033092.1), Mouse SIRPα (mSIRPα) gene sequence (Gene Bank sequence number: NM_001177647.2) and the lentiviral expression vector pLVX-puro (Clontech), the restriction sites EcoR I and BamH I were selected and the upstream and downstream primer sequences were designed by Genewise Biotechnology. The Human SIRPα primer sequence and the Mouse SIRPα primer sequence are shown in Tables 1 and 2 below:
[0039] Table 1 Human SIRPα primer sequence list
[0040] sequence name Sequence (5'-3') Sequence number plvx-hSp-F(EcoR I) CGGAATTCACCATGGAGCCCGCCGGCCCGG SEQ ID NO.11 plvx-hSp-R(BamH I) CGGGATCCTCACTTCCTCGGGACCTGGACGCTG SEQ ID NO.12
[0041] Table 2 Mouse SIRPα primer sequence list
[0042] sequence name Sequence (5'-3') Sequence number plvx-mSp-F(EcoR I) CGGAATTCACCATGGAGCCCGCCGGCCCGG SEQ ID NO.13 plvx-mSp-R(BamH I) CGGGATCCTCACTTCCTCTGGACCTGGACAC SEQ ID NO.14
[0043] (2) Peripheral blood was drawn from healthy volunteers and centrifuged with commercial lymphocyte separation medium (purchased from Tianjin Haoyang) to obtain human peripheral blood mononuclear cells (PBMCs). After red blood cells were lysed from mouse bone marrow cells, 20 ng / mL granulocyte-macrophage colony-stimulating factor (GM-CSF) was added to stimulate differentiation for 7 days to obtain mouse bone marrow-derived macrophages. RNA was extracted from human peripheral blood mononuclear cells (PBMC) or mouse bone marrow macrophages, and cDNA was obtained after reverse transcription. Human or mouse SIRPα gene fragments were obtained by PCR (the PCR reaction system was 20 μL, including 10 μL of 2×Mix premix, 1 μL of 10 μM primer F, 1 μL of 10 μM primer R, 1 μL of cDNA template, and 7 μL of sterile water). The required SIRPα gene was obtained after separation and purification by agarose gel electrophoresis. Finally, the SIRPα gene and pLVX-puro vector were digested with EcoR I enzyme and Bam HI enzyme, respectively, and recovered.
[0044] (3) Add 9 μL of double distilled water (ddH2O), 3 μL of SIRPα gene digested in step (2), 5 μL of pLVX-puro vector DNA digested in step (2), 2 μL of 10× Buffer, and 1 μL of T4 ligase in sequence, mix well, and ligate in a 16°C water bath overnight.
[0045] (4) Add 5 μL of the ligation product from step (3) to 100 μL of commercial competent cells DH5α (purchased from Beijing Quanshijin), mix well, place on ice for 30 min, heat shock at 42°C for 90 s, place on ice, add 600 μL of fresh LB medium, and culture on a shaking platform for 1 h.
[0046] (5) Spread the bacterial solution after shaking in step (4) on an LB plate with ampicillin resistance, select a single white colony for streaking culture, and then use an inoculation loop to pick up a single white colony on the plate and culture it in LB liquid culture medium. After culture, the gene sequencing is correct, which is the lentiviral expression vector pLVX-hSIRPα or pLVX-mSIRPα containing the target gene sequence.
[0047] (6) HEK-293T cells were cultured in DMEM medium (containing 10% FBS, 100 U / mL penicillin and 100 μg / mL streptomycin), and logarithmically growing cells were collected and counted. 6 The cells / well were inoculated into 6-well or 10 mm cell culture plates and cultured in a cell culture incubator at 37°C and 5% CO2.
[0048] (7) Set up tube A and tube B. When the density of the HEK-293T cells cultured in step (6) reaches 80-90% confluence, evenly add the transfection reagent in tube A to tube B, gently shake and mix, and incubate at room temperature for 20 minutes. During the incubation process, replace the HEK-293T cells with a confluence of 90% with fresh DMEM complete medium (the cells should be added slowly along the side wall of the well plate during the replacement process to avoid suspending the cells). After the incubation is completed, the mixed solution of tubes A and B is dripped into the DMEM medium containing HEK-293T cells. After culturing for 6 hours, the HEK-293T cells are replaced with fresh DMEM complete medium to produce viruses. After transfection for 48-72 hours, the culture medium containing virus particles is aspirated, and the cell debris is removed by centrifugation and filtered through a 0.45 μm pore size filter membrane to obtain the virus supernatant. The preparation of tube A and tube B is as follows:
[0049] Tube A: Pipette 7 μL Lipofectamine 3000 transfection reagent and add it dropwise into 250 μL Opti-MEM serum-free medium and mix well;
[0050] Tube B: Add 8 μg, 6 μg, and 2 μg of the lentiviral plasmid and auxiliary plasmid respectively in a ratio of pLVX-hSIRPα / pLVX-mSIRPα:psPAX2:pMD2.G=4:3:1, mix in 250 μL Opti-MEM serum-free medium, and add 32 μL of Lipofectamine 3000 transfection reagent to mix well.
[0051] (8) CHO-K1 cells were cultured in RPMI1640 medium and 2×10 5 cells / well are inoculated in a cell culture plate for culture. When the CHO-K1 cell density reaches 20-30%, polybrene with a final concentration of 8 μg / mL is added to the virus supernatant filtered in step (7), and then added to the cell culture plate containing CHO-K1 cells. After centrifugation at 1500×g at room temperature for 30 min, the plate is placed in an incubator. After overnight culture, the plate is replaced with a fresh serum-containing medium. After culture for 48 h, puromycin with a final concentration of 2 μg / mL is added to the medium to select stably transfected CHO-K1-hSIRPα or CHO-K1-mSIRPα cells. After culture for 72 h, the transfection efficiency can be detected by flow cytometry. If necessary, limiting dilution of cells can be performed to pick monoclonal cells.
[0052] 2. Analysis of the blocking effects of the parent peptide and derived peptides
[0053] (1) Sample tubes, negative control tubes, and positive control tubes were set up, and the CHO-K1-hSIRPα or CHO-K1-mSIRPα cells screened above were cultured in RMPI 1640 medium and the cells in the logarithmic growth phase were collected and counted. 5 cells / tube were divided into sample tubes, negative control tubes, and positive control tubes. Pre-cooled PBS buffer (PH=7.2) was added to the sample tubes, negative control tubes, and positive control tubes, and centrifuged at 4°C, 1500×g for 5 min to wash and then placed on ice.
[0054] (2) The purified parent peptide or derived peptide prepared in Example 1 was dissolved in a PBS buffer (PH = 7.2) containing 1% DMSO (dimethyl sulfoxide), and the purified parent peptide or derived peptide solution was taken into a sample tube (200 μL microcentrifuge tube), while the negative control tube and the positive control tube were respectively added with 50 μL of PBS buffer (PH = 7.2) containing 1% DMSO. Recombinant hCD47-Fc or mCD47-Fc protein (Sino Biological, China) at a concentration of 20 nM was added to the sample tube and the positive control tube, so that the final concentration of the polypeptide was 25 μM. After thorough mixing, the sample tube, the negative control tube, and the positive control tube were placed in an ice water bath and incubated for 30 minutes.
[0055] (3) Take 50uL of the mixture after incubation in step (2) and add it to the CHO-K1-hSIRPα or CHO-K1-mSIRPα cells in step (1) (the sample tube is CHO-K1-hSIRPα or CHO-K1-mSIRPα cells + recombinant hCD47-Fc or mCD47-Fc protein + parent peptide or derivative peptide solution; the negative control tube only adds CHO-K1-hSIRPα or CHO-K1-mSIRPα cells; the positive control tube is CHO-K1-hSIRPα or CHO-K1-mSIRPα cells + recombinant hCD47-Fc or mCD47-Fc protein), resuspend the cells, add 5uL of detection flow cytometry antibody (anti-human Fc PE) purchased from Thermo Fisher, mix well and place in an ice water bath for incubation for 30 minutes.
[0056] (4) After incubation in step (3), 1 mL of pre-cooled PBS buffer (PH = 7.2) was added to each tube of solution for centrifugal washing, and then 200 μL of PBS buffer (PH = 7.2) was added to resuspend the cells. The average fluorescence intensity of the cells was detected by flow cytometer (BECKMANCOULTER CytoFLEX), and the blocking rate was calculated based on the average fluorescence intensity of each group. The blocking rate was calculated as follows: blocking rate = (average fluorescence value of the positive control tube - average fluorescence value of the sample tube) / average fluorescence value of the positive control tube × 100%.
[0057] In addition, 9 groups of sample tubes and 1 group of control tubes were set up again, and each group had three sub-tubes, wherein the sample tubes were derived peptides (SEQ ID NO.2) to (SEQ ID NO.10), and the control tube was pep-20 peptide AWSATWSNYWRH (SEQ ID NO.15) with CD47 / SIRPa blocking function. The purified derived peptide and pep-20 peptide prepared in Example 1 were dissolved in PBS buffer (PH=7.2) containing 1% DMSO (dimethyl sulfoxide), and the purified derived peptide solution was taken into the sample tube (200 μL microcentrifuge tube), while the pep-20 peptide solution was added to the control tube. Recombinant hCD47-Fc or mCD47-Fc protein (Sino Biological, China) at a concentration of 20 nM was added to both the sample tube and the control tube, so that the final concentration of the polypeptide in the sample tube and the control tube was 100 μM, and the remaining steps were the same as steps (1)-(4).
[0058] Experimental results:
[0059] Figure 2 or Figure 3 The experimental results are shown in Figure 1 when the concentration of the parent peptide or the derived peptide is 25 μM or 100 μM. Figure 2It can be seen that the stronger the fluorescence, the smaller the blocking effect. The negative control tube CHO-K1 m / hSIRPα has no fluorescence, and the positive control tube m / hCD47 protein has the strongest fluorescence. The parent peptide WSMTWWNYW (SEQ ID NO.1) blocks the interaction between human CD47 / SIRPα protein or mouse CD47 / SIRPα protein better than the derived peptides WSMTWSNYW (SEQ ID NO.3) and WSATWWNYW (SEQ ID NO.7).
[0060] Depend on Figure 3 It can be seen that when blocking human CD47 / SIRPα protein, the blocking effects of the derived peptide WSMTWSNYW (SEQ ID NO.3) and the derived peptide WSATWSNMW (SEQ ID NO.10) are higher than that of the control group pep-20 peptide AWSATWSNYWRH (SEQ IDNO.15); when blocking mouse CD47 / SIRPα protein, the blocking effects of WSQTWSNYW (SEQ ID NO.2), WSMTWSNYW (SEQ IDNO.3), WSYTWSNYW (SEQ ID NO.4), WSWTWSNYW (SEQ ID NO.5), WSATWWNYW (SEQ ID NO.7), and WSATWSNMW (SEQ ID NO.10) are higher than that of the control group pep-20 peptide AWSATWSNYWRH (SEQ IDNO.15). Therefore, when the working concentration of the derived peptides was 100 μM, WSMTWSNYW (SEQ ID NO. 3) and WSATWSNMW (SEQ ID NO. 10) had the best effect in blocking human or mouse CD47 / SIRPα protein.
[0061] In summary, the higher the peptide concentration, the better the blocking effect. At low concentrations, the blocking effect of the parent peptide WSMTWWNYW (SEQ ID NO. 1) is significantly better than that of the derived peptide.
[0062] Example 3: Effects of the parent peptide and derived peptides on the phagocytic effect of primary macrophages in vitro
[0063] The parent peptide (SEQ ID NO.1) and the derived peptides (SEQ ID NO.2)-(SEQ ID NO.10) are all L-configuration amino acids, so the parent peptide WSMTWWNYW (SEQ ID NO.1) with the best blocking effect or the derived peptides obtained after the parent peptide (SEQID NO.1) was modified with fatty acids were selected to explore the effects on phagocytes.
[0064] 1. In vitro induction of macrophages
[0065] The specific steps include:
[0066] C57BL / 6 mice were dissected after neck removal and surface disinfection. The thighs of the mice were removed, the muscle tissues were removed, the patella, fibula, and tibia were taken, the bone joints were cut, and the DMEM medium was extracted with a syringe to flush out the bone marrow cells, and the bone marrow cells were blown and dispersed with a pipette. After filtering through a filter, the cells were collected by centrifugation at 4°C and 1500×g for 5 min, and the red blood cells were lysed at 4°C for 5 min, and then PBS buffer (PH=7.2) was added and centrifuged and washed twice, and then 2 mL of DMEM medium was added to resuspend the cells (the bone marrow cell clusters attached to the bottom after centrifugation were reblown into single cell suspension) and counted, and the cell density was adjusted to 1×10 6 cells / mL and then cultured in DMEM medium, and granulocyte-macrophage colony-stimulating factor GM-CSF (Peprotech, USA) was added to the DMEM medium to make the final concentration of 20 ng / mL. After 3 days, half of the medium was replaced with fresh medium, and the non-adherent cells were discarded and granulocyte-macrophage colony-stimulating factor GM-CSF (Peprotech, USA) was added with a final concentration of 20 ng / mL. The macrophages obtained after culturing for 7 days were used for subsequent experiments.
[0067] 2. CFSE labeling of tumor cells
[0068] The specific steps include:
[0069] (1) Add DMSO (dimethyl sulfoxide) to the CFSE fluorescent dye to fully dissolve the dye and mix well to prepare a CFSE stock solution with a concentration of 10 mM;
[0070] (2) MC38 colorectal cancer cells to be labeled were collected by centrifugation and washing with PBS buffer (pH = 7.2) and the cell density was adjusted to 5 × 10 6 cells / mL, after thorough mixing, pipette 1 mL of cell suspension into the bottom of a 15 mL centrifuge tube and place at room temperature;
[0071] (3) Dilute the CFSE stock solution prepared in step (1) with PBS buffer (PH = 7.2) to a final concentration of 1 μM, tilt the centrifuge tube containing MC38 colorectal cancer tumor cells and slowly add CFSE dye with a final concentration of 1 μM to the wall of the centrifuge tube, slowly cover the centrifuge tube, quickly invert the centrifuge tube and vortex to quickly mix the dye, and incubate at room temperature in the dark for 10 min;
[0072] (4) Add 6 times or more of the volume of pre-cooled DMEM complete medium to the centrifuge tube after incubation in step (3), mix thoroughly, and incubate in an ice water bath for 5 min to terminate labeling; wash the cells twice with complete medium by centrifugation at 4°C and 1500×g for 5 min to obtain labeled tumor cells, which are then placed on ice for later use.
[0073] 3. In vitro macrophage phagocytosis experiment:
[0074] The phagocytosis experiment consists of the following steps:
[0075] (1) Precooled serum-free culture medium (Gibco, USA) was added to a low-adsorption 96-well plate, and 100 μM of the parent peptide WSMTWWNYW (SEQ ID NO.1) prepared in Example 1, the derivative peptide obtained by fatty acid modification of the parent peptide (SEQ ID NO.1), and 100 μM PBS buffer (PH = 7.2) were added, respectively. The control group was added with PBS buffer (PH = 7.2). Then, 1×10 6 cells / well labeled MC38 colorectal cancer tumor cells, incubated in an ice water bath for 30 min;
[0076] (2) The cultured macrophages were added to the low-adsorption 96-well plates incubated in step (1), and the final concentration of macrophages was 1×10 5 cells / well, gently shake to mix, place in a cell culture incubator at 37°C for 4 hours, collect macrophages after the incubation, add 50uL 10% SD rat serum (take SD rat blood, let it stand for 2 hours, centrifuge at 12000 rpm, and take the upper serum), incubate for 15 minutes to block Fcγ receptors, add anti-mouse F4 / 80 antibody, mix well, place in an ice water bath and incubate for 30 minutes, add 1mL pre-cooled FACS Buffer and centrifuge to wash, resuspend the cells, and finally add 4μL 7-aminoactinomycin (7-AAD) dye to each tube, mix well, incubate in the dark for 5 minutes, filter the test samples after incubation in the dark, transfer them to flow sample tubes and detect them by flow cytometer (BECKMAN COULTER CytoFLEX).
[0077] like Figure 4As shown, the phagocytic rates of the parent peptide (SEQ ID NO.1) and the derivative peptides obtained by modifying the parent peptide (SEQ ID NO.1) with fatty acids were higher than those of the control group, among which the parent peptide (SEQ ID NO.1) had the best phagocytic effect, because the phagocytic function of macrophages on tumor cells was enhanced after incubation with CD47 blocking peptide.
[0078] Example 4: Exploring the anti-tumor effect of the derived peptides in the MC38 colorectal cancer transplant model
[0079] Because the parent peptide (SEQ ID NO.1) and the derived peptides (SEQ ID NO.2)-(SEQ ID NO.10) are all L-configuration amino acids and are not resistant to enzymatic degradation, in vivo experiments cannot be performed. Therefore, the derived peptides obtained by modifying the parent peptide (SEQ ID NO.1) with fatty acids were used to enhance the half-life and anti-enzymatic stability for subsequent experiments.
[0080] 1. Test the anti-tumor effect
[0081] The specific steps include:
[0082] (1) MC38 colorectal cancer cells were cultured in a cell culture dish containing DMEM medium (containing 10% FBS, 100 U / mL penicillin and 100 μg / mL streptomycin), and then the cell culture dish was placed in a cell culture incubator at 37°C and 5% CO2. Then, MC38 colorectal cancer cells in the logarithmic growth phase were collected, washed by centrifugation with pre-cooled PBS buffer (PH=7.2), and then counted and the cell density was adjusted to 5×10 6 cells / mL, placed in an ice water bath, selected 6-8 week old C57BL / 6 mice for the experiment, and the cells were plated at 1×10 6 The cell density of cells / mouse was subcutaneously inoculated on the right back of C57BL / 6 mice to construct the MC38 xenograft tumor model;
[0083] (2) Tumor bearing for about 7 days (tumor grows to 30-70 mm 3 ) and then observe the tumor formation of mice. Mice were randomly divided into groups according to tumor volume. The weight and tumor volume of mice were measured every other day, and drug administration was started on the same day of recording. The tumor volume was calculated by the formula: V = 1 / 2 × a (length) × b (width) × c (height);
[0084] (3) Grouping and administration: A treatment group and a control group were set up. The mice in the treatment group were intraperitoneally injected with 0.75 mg / kg of the derivative peptide obtained after the fatty acid-modified parent peptide (SEQ ID NO.1), and the mice in the control group were injected with an equal amount of PBS buffer (PH = 7.2). The drugs were administered continuously for 14 days.
[0085] Depend on Figure 5 It can be seen that as the number of days of MC38 tumor inoculation increases, the tumor volume of the drug administration group and the control group increases. At the beginning of the inoculation, due to the short inoculation time, the difference in tumor volume between the drug administration group and the control group was not large, but as the number of days of inoculation increases, the tumor volume of the drug administration group is only half of that of the control group. Therefore, the derivative peptide obtained after fatty acid modification of the parent peptide (SEQ ID NO.1) can significantly inhibit the growth of mouse tumors after intraperitoneal injection.
[0086] In addition, in order to prove the safety of the derivative peptide modified by fatty acid, blood samples were collected from the mice in the treatment group and the control group for routine blood tests after the treatment to analyze the hematological parameters of the derivative peptide modified by fatty acid treatment group and the PBS buffer (PH=7.2) control group.
[0087] Depend on Figure 6 It can be seen that the red blood cell count, hematocrit, hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin content, mean corpuscular hemoglobin concentration and coefficient of variation of red blood cell distribution width in the drug administration group were basically the same as those in the control group, and no side effects were found after drug administration. Therefore, the drug administration group completely avoided the blood toxicity that CD47 antibodies are prone to produce.
[0088] The above is a preferred embodiment of the present invention. It should be pointed out that a person skilled in the art can make several improvements and modifications without departing from the principle of the present invention. These improvements and modifications are also considered to be within the scope of protection of the present invention. Sequence Listing <110> Sun Yat-sen University <120> A parent peptide or derived peptide with CD47 / SIRPα blocking effect and its application <160> 15 <170> SIPOSequenceListing 1.0 <210> 1 <211> 9 <212> PRT <213> Artificial Sequence <400> 1 Trp Ser Met Thr Trp Trp Asn Tyr Trp 1 5 <210> 2 <211> 9 <212> PRT <213> Artificial Sequence <400> 2 Trp Ser Gln Thr Trp Ser Asn Tyr Trp 1 5 <210> 3 <211> 9 <212> PRT <213> Artificial Sequence <400> 3 Trp Ser Met Thr Trp Ser Asn Tyr Trp 1 5 <210> 4 <211> 9 <212> PRT <213> Artificial Sequence <400> 4 Trp Ser Tyr Thr Trp Ser Asn Tyr Trp 1 5 <210> 5 <211> 9 <212> PRT <213> Artificial Sequence <400> 5 Trp Ser Trp Thr Trp Ser Asn Tyr Trp 1 5 <210> 6 <211> 9 <212> PRT <213> Artificial Sequence <400> 6 Trp Ser Arg Thr Trp Ser Asn Tyr Trp 1 5 <210> 7 <211> 9 <212> PRT <213> Artificial Sequence <400> 7 Trp Ser Ala Thr Trp Trp Asn Tyr Trp 1 5 <210> 8 <211> 9 <212> PRT <213> Artificial Sequence <400> 8 Trp Ser Ala Thr Trp Ser Asn Trp Trp 1 5 <210> 9 <211> 9 <212> PRT <213> Artificial Sequence <400> 9 Trp Ser Ala Thr Trp Ser Asn Arg Trp 1 5 <210> 10 <211> 9 <212> PRT <213> Artificial Sequence <400> 10 Trp Ser Ala Thr Trp Ser Asn Met Trp 1 5 <210> 11 <211> 30 <212> PRT <213> Artificial Sequence <400> 11 Cys Gly Gly Ala Ala Thr Thr Cys Ala Cys Cys Ala Thr Gly Gly Ala 1 5 10 15 Gly Cys Cys Cys Gly Cys Cys Gly Gly Cys Cys Cys Gly Gly 20 25 30 <210> 12 <211> 33 <212> PRT <213> Artificial Sequence <400> 12 Cys Gly Gly Gly Ala Thr Cys Cys Thr Cys Ala Cys Thr Thr Cys Cys 1 5 10 15 Thr Cys Gly Gly Gly Ala Cys Cys Thr Gly Gly Ala Cys Gly Cys Thr 20 25 30 Gly <210> 13 <211> 30 <212> PRT <213> Artificial Sequence <400> 13 Cys Gly Gly Ala Ala Thr Thr Cys Ala Cys Cys Ala Thr Gly Gly Ala 1 5 10 15 Gly Cys Cys Cys Gly Cys Cys Gly Gly Cys Cys Cys Gly Gly 20 25 30 <210> 14 <211> 31 <212> PRT <213> Artificial Sequence <400> 14 Cys Gly Gly Gly Ala Thr Cys Cys Thr Cys Ala Cys Thr Thr Cys Cys 1 5 10 15 Thr Cys Thr Gly Gly Ala Cys Cys Thr Gly Gly Ala Cys Ala Cys 20 25 30 <210> 15 <211> 12 <212> PRT <213> Artificial Sequence <400> 15 Ala Trp Ser Ala Thr Trp Ser Asn Tyr Trp Arg His 1 5 10
Claims
1. A parent peptide or a derivative peptide thereof having a CD47 / SIRPα blocking effect, It is characterized in that The amino acid sequence of the parent peptide is shown in SEQ ID NO.
1. The derivative peptide is obtained by modifying the N-terminus of the parent peptide with fatty acids. The parent peptide is modified with fatty acids using PEG. 4 The fatty acid Fmoc-Lys(Pal-Glu-OtBu)-OH is connected to the N-terminus of the parent peptide, and the derivative peptide obtained after the parent peptide is modified with fatty acid has the following structural formula:
2. The parent peptide or its derivative peptide having CD47 / SIRPα blocking effect according to claim 1, It is characterized in that The amino acid configuration of the parent peptide is independently selected from D-form or L-form.
3. The parent peptide or its derivative peptide having CD47 / SIRPα blocking effect according to claim 1, It is characterized in that The parent peptide or its derivative peptide also includes a pharmaceutically acceptable salt of the parent peptide or its derivative peptide.
4. Use of the parent peptide or its derivative peptide having CD47 / SIRPα blocking effect according to any one of claims 1 to 3 in the preparation of anti-tumor drugs, It is characterized in that The tumor is colorectal cancer.
5. The use according to claim 4, It is characterized in that The dosage forms of the anti-tumor drug include injection, oral solution, powder, tablet, pill, aerosol, ointment and capsule.
6. The use according to claim 4, It is characterized in that The anti-tumor drug may be added with one or more pharmaceutically acceptable excipients, which include conventional diluents, fillers, adhesives, wetting agents, absorption enhancers, surfactants, lubricants or stabilizers in the pharmaceutical field.
